About the Project
Commercial long acting pharmaceutical formulations have been developed to fulfil clinical needs, of improving both patient adherence and long-term therapeutic outcomes [1-3]. Typical examples of such products can be found for delivering contraceptive and anti-psychotic drugs. This fully funded PhD studentship in cooperation with Janssen will develop a new formulation platform addressing a number of drawbacks of the currently available formulation options including cost (both or production and excipient materials), duration of action, ease of manufacture and hydrolytic stability. The new formulation platform will enable the engineering of novel materials that exhibit suitable phase transformation from injectable liquids to semisolid depots after deposition in the body. The student will work in the state-of-the-art drug delivery lab at the School of Pharmacy and receive excellent training on advanced materials sciences research and transferable skills to ensure they can build a successful career beyond their PhD. The project is a close research collaboration with Janssen. The student will have a fixed period of exchange embedded within Janssen’s R&D team and gain insights into industrial research and product development.
For more information on the supervisor for this project, please go here https://people.uea.ac.uk/sheng_qi
Type of project: PhD
Start Date: December 2020
Mode of Study: Full-time
This PhD studentship is funded for 3 years by Janssen Research and Development. Funding is available to UK/EU applicants only and includes Home/EU tuition fees an annual stipend of £15,459 in year 1, rising to £16,400 in year 3.
i) Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy. Adv Drug Deliv Rev. 2016 Aug 1; 103: 144–156
ii) Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nature Communications volume 10, Article number: 4324 (2019)
iii) Making the Leap from Daily Oral Dosing to Long-Acting Injectables: Lessons from the Antipsychotics. Mol. Pharmaceutics 2014, 11, 6, 1739-1749